+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors



Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors



Case Reports in Gastroenterology 12(3): 704-708



Immune checkpoint inhibitors (ICPIs) are novel therapeutic agents targeting a variety of cancers by enhanced T cell activation. Immune-related adverse events (irAEs) commonly occur with ICPI use and can affect multiple organ systems including the gastrointestinal tract. Due to irAEs, the use of ICPIs is limited in autoimmune diseases. We present a case of microscopic colitis diagnosed after the initiation of nivolumab and a case of ipilimumab colitis and Clostridium difficile in the setting of Crohn's colitis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066079004

Download citation: RISBibTeXText

PMID: 30631256

DOI: 10.1159/000493183


Related references

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. Thoracic Cancer 2019, 2019

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade. JAMA Oncology 2019, 2019

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. International Immunopharmacology 62: 29-39, 2018

Severe neurologic complications of immune checkpoint inhibitors: a single-center review. Journal of Neurology 2018, 2018

Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways. Biodrugs 32(5): 481-497, 2018

Autoimmunologische Reaktionen bei Immun-Checkpoint-Inhibitoren; Autoimmune reactions to immune checkpoint inhibitors;. Zeitschrift für Rheumatologie 76(S2): 57-62, 2017

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clinical and Translational Medicine 7(1): 32, 2018

Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study. Journal of Clinical Medicine Research 11(4): 225-236, 2019

Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14 + and CD16 + monocytes driving an innate immune response. Journal of Cutaneous Pathology 2019, 2019

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia. Frontiers in Pharmacology 10: 454, 2019

Immune-related adverse events of immune checkpoint inhibitors and the impact of sex-what we know and what we need to learn. Annals of Oncology 29(4): 1067, 2018

Do immune-related adverse events correlate with response to immune checkpoint inhibitors?. ImmunoTherapy 11(4): 257-259, 2019

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncology 2(10): 1346-1353, 2016

Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors : Immune-mediated side effects. Der Urologe. Ausg. a 57(5): 543-551, 2018

Management of immune-related adverse events during treatment with immune checkpoint inhibitors. Recenti Progressi in Medicina 107(8): 407-413, 2018